Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

• DOI: 10.1200/jco.2011.29.15_suppl.e14653
• Publication Date: 2017-02-23T13:58:03Z
• Authors: J. Yi; S. Thongprasert; D. Doval; J. Lee; M. N. Cho; S. H. Park; J. O. Park; Y. S. Park; W. K. Kang; H. Y. Lim
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e14653 Background: Biliary tract carcinoma (BTC) is rare in the West, but not uncommon in Asia and is highly fatal malignancy. While gemcitabine-based regimen is considered as reasonable option for...